HeartFlow is a medical equipment manufacturer that uses CT-scanned 3D modelling to assess and analyze a patient's heart and arteries. This non-invasive process can help assess the risks of Coronary Artery Disease (CAD) and strategize the appropriate treatment.
As the world’s leading cause of death, CAD is a worthy target for improved diagnosis and treatment. HeartFlow's approach enables clinicians to deliver more effective treatments faster, making CAD more manageable than ever before.
The company has a long history of awards and innovations, adopting technological advancements as they happen. It successfully launched its IPO in 2021, although a 2022 merger with Longview Acquisitions was called off due to unfavourable market conditions. Despite this, the company remains steadfast, unveiling new technology that ensures better treatment for CAD patients.
Steph
Company Specialist at Welcome to the Jungle